Tesamorelin: what the research actually says
Most peptide pages on this site are about compounds with promising animal data and an evidence gap where human trials should be. Tesamorelin is the exception, and it's useful precisely because of that contrast: it shows what it actually takes for a peptide to clear the FDA's bar, and how narrow an "approved" label can be even when it's real.
What tesamorelin is
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), made by Theratechnologies and sold under the brand names Egrifta and, since a 2019 reformulation, Egrifta SV. It works by stimulating the pituitary gland to release the body's own growth hormone.
FDA approval: what it actually covers
The FDA approved tesamorelin (BLA 022505) in November 2010.1 Its approved indication is narrow and specific: "reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy." The label is explicit about the limits of that approval: "EGRIFTA SV is not indicated for weight loss management as it has a weight neutral effect."1 That single sentence separates tesamorelin from most peptides marketed for general fat loss: the FDA-reviewed data specifically found it does not work that way overall, even though it reduces a particular type of fat.
What the evidence shows, for its approved use
A 2026 meta-analysis pooling five randomized controlled trials of tesamorelin in HIV-associated lipodystrophy found statistically significant reductions in visceral adipose tissue (average −27.71 cm²), trunk fat (−1.18 kg), and hepatic fat percentage (−4.28%), plus a significant increase in lean body mass (+1.42 kg) — all with P values below 0.001.2 Consistent with the FDA label, the same analysis found no significant change in overall BMI, confirming its "weight neutral" characterization. Reported adverse events included arthralgia, muscle pain, tingling sensations, and injection-site reactions, without significant disruption to blood glucose.2
"Insulin and GLP-1s are designed for specific disease, so we know who's a good candidate for them."
— Dr. Anthony C. Tam, MD, family and sports medicine physician, Henry Ford Health, discussing what separates well-studied, approved peptide drugs from newer, unapproved ones, in the American Medical Association (April 2026). Tesamorelin follows the same pattern: a defined patient population, defined trials, and FDA-reviewed prescribing guidance.
What "approved" looks like, concretely
| Tesamorelin (Egrifta / Egrifta SV) | Typical unapproved wellness peptide | |
|---|---|---|
| FDA status | Approved (2010; reformulated 2019) | Not approved |
| Human trials | Multiple published randomized controlled trials | Usually none published |
| Indication | One defined condition, on the label | Broad, undefined marketing claims |
| Manufacturing | FDA-regulated pharmaceutical production | Unverified "research use only" vials |
| Access | Prescription, licensed pharmacy | Direct-to-consumer online sale |
The off-label risk worth knowing about
Because tesamorelin raises growth hormone, it's sometimes sought outside its approved use, for general fat loss, muscle gain, or anti-aging, by people who don't have HIV-associated lipodystrophy. That use falls outside the population the trials studied and outside what the FDA reviewed. An approved drug used off-label, without the diagnosis and monitoring it was studied for, loses much of the safety margin that made it approvable in the first place.
Sources
- U.S. Food & Drug Administration, Drugs@FDA — Egrifta (tesamorelin), BLA 022505, approval history and label.
- Obesity Research & Clinical Practice (2026) — "Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin... a meta-analysis of randomized controlled trials."
- American Medical Association — "What doctors want patients to know about injectable peptides" (April 2026).